Diabetic dyslipidaemia is a complex condition characterized by multiple lipid and lipoprotein abnormalities, including increased plasma triglycerides, low HDL cholesterol, small dense LDL, and excessive postprandial lipemia. These abnormalities are closely linked metabolically and contribute to atherogenesis. The key issue is understanding the mechanisms behind the increased production of large VLDL 1 particles in Type 2 diabetes. Recent research highlights the role of insulin signaling, SREBP-1C, and lipid availability in the liver in regulating VLDL assembly and secretion. The liver's ability to regulate triglyceride incorporation into VLDL particles remains incompletely understood, but factors such as low insulin signaling, increased SREBP-1C, and excess "polar molecules" in hepatocytes are implicated. The transcription factors PPARs, SREBP-1, and LXRs are key regulators of lipid metabolism in the liver and represent potential targets for new therapies. The heterogeneity of TRLs, including VLDL 1 and VLDL 2 particles, plays a critical role in the atherogenic lipid triad. Postprandial lipemia is a significant feature of diabetic dyslipidaemia, with increased VLDL 1 particles contributing to elevated triglycerides. The metabolism of TRLs involves lipolysis by LPL and hepatic lipase, and the clearance of remnants by liver receptors. The dysregulation of VLDL metabolism in Type 2 diabetes leads to the overproduction of VLDL 1 particles, which can saturate metabolic capacity and contribute to postprandial lipemia. The mechanisms behind this include impaired insulin signaling, increased de novo lipogenesis, and altered lipid availability in hepatocytes. The accumulation of triglycerides in the liver is closely linked to insulin resistance and dyslipidaemia. The atherogenicity of small dense LDL is due to its increased susceptibility to oxidation and its enhanced binding to intimal proteoglycans. HDL metabolism is also affected, with reduced concentrations and altered composition in Type 2 diabetes. The primary targets for lipid management in Type 2 diabetes are small dense LDL, remnant particles, and low HDL levels. LDL cholesterol is the first priority for lipid lowering, with an optimal level of <2.6 mmol/l. Statin therapy has shown significant benefits in reducing vascular events in diabetic patients.Diabetic dyslipidaemia is a complex condition characterized by multiple lipid and lipoprotein abnormalities, including increased plasma triglycerides, low HDL cholesterol, small dense LDL, and excessive postprandial lipemia. These abnormalities are closely linked metabolically and contribute to atherogenesis. The key issue is understanding the mechanisms behind the increased production of large VLDL 1 particles in Type 2 diabetes. Recent research highlights the role of insulin signaling, SREBP-1C, and lipid availability in the liver in regulating VLDL assembly and secretion. The liver's ability to regulate triglyceride incorporation into VLDL particles remains incompletely understood, but factors such as low insulin signaling, increased SREBP-1C, and excess "polar molecules" in hepatocytes are implicated. The transcription factors PPARs, SREBP-1, and LXRs are key regulators of lipid metabolism in the liver and represent potential targets for new therapies. The heterogeneity of TRLs, including VLDL 1 and VLDL 2 particles, plays a critical role in the atherogenic lipid triad. Postprandial lipemia is a significant feature of diabetic dyslipidaemia, with increased VLDL 1 particles contributing to elevated triglycerides. The metabolism of TRLs involves lipolysis by LPL and hepatic lipase, and the clearance of remnants by liver receptors. The dysregulation of VLDL metabolism in Type 2 diabetes leads to the overproduction of VLDL 1 particles, which can saturate metabolic capacity and contribute to postprandial lipemia. The mechanisms behind this include impaired insulin signaling, increased de novo lipogenesis, and altered lipid availability in hepatocytes. The accumulation of triglycerides in the liver is closely linked to insulin resistance and dyslipidaemia. The atherogenicity of small dense LDL is due to its increased susceptibility to oxidation and its enhanced binding to intimal proteoglycans. HDL metabolism is also affected, with reduced concentrations and altered composition in Type 2 diabetes. The primary targets for lipid management in Type 2 diabetes are small dense LDL, remnant particles, and low HDL levels. LDL cholesterol is the first priority for lipid lowering, with an optimal level of <2.6 mmol/l. Statin therapy has shown significant benefits in reducing vascular events in diabetic patients.